Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-phosphatidylinositol-4-phosphate 5-kinase
-
-
-
-
1-phosphatidylinositol-4-phosphate kinase
-
-
-
-
1-phosphatidylinositol-5-phosphate 4-kinase
Diphosphoinositide kinase
-
-
-
-
pan-phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 4-kinase
-
-
phosphatidylinositol 4-phosphate 5-kinase gamma
-
-
phosphatidylinositol 5 phosphate 4-kinase
phosphatidylinositol 5-phosphate 4-kinase
phosphatidylinositol 5-phosphate 4-kinase gamma
phosphatidylinositol 5-phosphate 4-kinase-alpha
-
-
phosphatidylinositol 5-phosphate, 4-kinase alpha
-
isoform
phosphatidylinositol 5-phosphate, 4-kinase beta
-
isoform
phosphatidylinositol phosphate kinase II gamma
phosphatidylinositol-5-phosphate 4-kinase
-
-
phosphatidylinositol-5-phosphate 4-kinase alpha
-
phosphatidylinositol-5-phosphate 4-kinase gamma
-
-
phosphatidylinositol-5-phosphate 4-kinase type II
-
-
phosphatidylinositol-5-phosphate 4-kinase type II beta
-
-
phosphatidylinositol-5-phosphate 4-kinase type-2 gamma
-
-
phosphatidylinositol-5-phosphate 4-kinase, type II, beta
isoform
PI-5-phosphate 4-kinase type II
-
-
PtdIns(4)P-5-kinase B isoform
-
-
-
-
PtdIns(4)P-5-kinase C isoform
-
-
-
-
type II alpha phosphatidylinositol-5-phosphate 4-kinase
type II phosphatidylinositol 4-kinase
-
-
type II phosphatidylinositol 4-kinase beta
-
-
type II PI-5-P 4-kinase
-
-
type II PIP kinase
-
-
-
-
type II PtdIns 4-kinase
-
-
type II PtdIns 4-kinase beta
-
-
type IIbeta phosphatidylinositol 5-phosphate 4-kinase
1-phosphatidylinositol-5-phosphate 4-kinase

-
1-phosphatidylinositol-5-phosphate 4-kinase
-
phosphatidylinositol 5 phosphate 4-kinase

-
-
phosphatidylinositol 5 phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase

-
-
phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase
-
phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase
-
-
phosphatidylinositol 5-phosphate 4-kinase gamma

-
-
phosphatidylinositol 5-phosphate 4-kinase gamma
-
-
phosphatidylinositol phosphate kinase II gamma

-
phosphatidylinositol phosphate kinase II gamma
-
PI5P4K

-
-
PI5P4Kalpha

-
isoform
PI5P4Kbeta

-
isoform
PI5P4Kgamma

-
isoform
PIP4K

-
-
Pip4k2a

-
isoform
Pip4k2b

-
isoform
PIP4Kalpha

-
-
PIP4Kbeta

-
-
PIP4Kgamma

isoform
PIPKIIalpha

-
-
PIPkinIIbeta

-
-
PtdIns5P 4-kinase

-
PtdIns5P-4-kinase

-
-
type II alpha phosphatidylinositol-5-phosphate 4-kinase

-
-
type II alpha phosphatidylinositol-5-phosphate 4-kinase
-
-
type II alpha phosphatidylinositol-5-phosphate 4-kinase
-
-
-
type IIbeta phosphatidylinositol 5-phosphate 4-kinase

-
-
type IIbeta phosphatidylinositol 5-phosphate 4-kinase
-
type IIbeta PIPkin

-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol 3-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate
-
poor substrate compared to 1-phosphatidyl-1D-myo-inositol 5-phosphate
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + dipalmitoyl-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + dipalmitoyl-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate

ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate

ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
663208, 721493, 721525, 723602, 737401, 737789, 738171, 758575, 758945, 759023, 759615 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
phosphorylation at the D-4 position
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
the enzyme may have an important role in synthesis of phosphatidylinositol bisphosphate in the endoplasmic reticulum
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
type II PIP kinases are physiological targets for protein kinase D phosphorylation. This modification is likely to regulate inositol lipid turnover by inhibition of these lipid kinases
-
-
?
additional information

?
-
-
the enzyme phosphorylated His-tagged ANAC078 protein at the C-terminus
-
-
?
additional information
?
-
-
although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduces rather than increases phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K, this reduction in PI-3,4,5-P3 levels results in decreased activation of the downstream protein kinase Akt/PKB, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, results in Akt activation, and this effect is partially reversed by PIP4K IIbeta, PIP4K IIbeta expression does not impair insulin-dependent association of PI3K with insulin receptor substrate 1 IRS1 but abbreviates Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate

ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
5' phosphorylation
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate

ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
663208, 721493, 721525, 723602, 737401, 737789, 738171, 758575, 758945, 759023, 759615 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
ir
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
the enzyme may have an important role in synthesis of phosphatidylinositol bisphosphate in the endoplasmic reticulum
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol 5-phosphate
ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate
-
type II PIP kinases are physiological targets for protein kinase D phosphorylation. This modification is likely to regulate inositol lipid turnover by inhibition of these lipid kinases
-
-
?
additional information

?
-
-
although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduces rather than increases phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K, this reduction in PI-3,4,5-P3 levels results in decreased activation of the downstream protein kinase Akt/PKB, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, results in Akt activation, and this effect is partially reversed by PIP4K IIbeta, PIP4K IIbeta expression does not impair insulin-dependent association of PI3K with insulin receptor substrate 1 IRS1 but abbreviates Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
additional information
?
-
-
isozyme PIP4Kbeta interacts in vitro and in vivo with the PIP4Kalpha isoform. PIP4Kbeta has 2000fold less activity towards 1-phosphatidyl-1D-myo-inositol 5-phosphate compared with PIP4Kalpha, the majority of enzyme activity associated with PIP4Kbeta comes from its interaction with PIP4Kalpha
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
-
-
(2E)-2-(3,4-dihydroxybenzoyl)-3-(4-hydroxy-3-iodo-5-methoxyphenyl)prop-2-enenitrile
-
-
(2E)-4-(dimethylamino)-N-[1-[(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)acetyl]piperidin-4-yl]but-2-enamide
-
-
(2Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)prop-2-enenitrile
-
-
(3E)-5-amino-3-[(2Z)-1-cyano-2-(3H-indol-3-ylidene)ethylidene]-2,3-dihydro-1H-pyrazole-4-carbonitrile
-
-
(3Z)-2-amino-4-(3,4,5-trihydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
-
-
(E)-N-(4-(5-((2,5-dioxopyrrolidin-3-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-1-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)-3-methylurea
-
-
(Z)-2-imino-5-((5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-(trifluoromethyl)phenyl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-2-imino-5-((5-(4-methoxynaphthalen-1-yl)pyridin-3-yl)methylene)thiazolidin-4-one
-
-
(Z)-4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)-N-methylbenzenesulfonamide
-
-
(Z)-5-((5-(4-(dimethylamino)phenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-5-((5-(4-fluorophenyl)pyridin-3-yl)methylene)-2-iminothiazolidin-4-one
-
-
(Z)-N-(3-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(2-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)-methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxo-oxazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)acetamide
-
-
(Z)-N-(4-(5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
i.e. CVM-05-002, potent and selective inhibitor for isoform PI5P4Kalpha
(Z)-N-(4-(6-amino-5-((2-imino-4-oxothiazolidin-5-ylidene)methyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
2,4-diamino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
3-(trifluoromethyl)phenyl 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylate
-
3-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-(3-phenoxyphenyl)pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-methyl-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(2,2,2-trifluoroethoxy)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
-
4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-N-[4-methyl-3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(benzylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(dimethylamino)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(methylsulfanyl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-(piperidin-1-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-hydroxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-methoxy-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(2,2-dimethylpropyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[(tert-butylcarbamoyl)amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-2-[[(1-methyl-1H-pyrazol-5-yl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-amino-N-(1,3-benzothiazol-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-(1-benzothiophen-5-yl)-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]-2-(3,4,4-trimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide
-
4-amino-N-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)cyclohexane-1-carboxamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(2-methyl-2H-benzimidazol-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[6-(4-methylanilino)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(3-[[7-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(4-methyl-3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-4-yl]amino]phenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-(5-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]-2-methylphenyl)benzamide
-
-
4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]-N-[(3-[[6-(1H-indol-3-yl)pyrimidin-4-yl]amino]phenyl)methyl]benzamide
-
-
5-[3-(methylsulfonyl)phenyl]-4-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]thieno[2,3-d]pyrimidine
-
-
AG-538
-
at a concentration of 0.02 mM, AG-538 induces an almost complete inhibition of isoform PI5P4Kalpha and inhibits isoforms PI5P4Ks beta and gamma by 90% and 85%, respectively
N-(3-((5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)amino)phenyl)acetamide
-
-
N-(3-((5-(4-(Mmthylsulfonamido)phenyl)pyridin-3-yl)oxy)phenyl)acetamide
-
-
N-(3-(5-(4-(methylsulfonamido)phenyl)pyridin-3-yl)phenyl)acetamide
-
-
N-(3-[[6-([1,1'-biphenyl]-3-yl)pyrimidin-4-yl]amino]phenyl)-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-(4-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(2-oxoindolin-4yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(4-(5-(4-(3-methylureido)phenyl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(5-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-(6-(5-(1H-indol-4-yl)pyridin-3-yl)phenyl)methanesulfonamide
-
-
N-[3-([6-[([1,1'-biphenyl]-3-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
N-[3-([6-[([1,1'-biphenyl]-4-yl)amino]pyrimidin-4-yl]amino)phenyl]-4-[[(2E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
-
-
piperine
-
complete inhibition at 0.1 mM
tyrphostin
-
ATP-competitive inhibitors, i.e. tyrosine phosphorylation inhibitors, of isozyme PI5P4Kalpha
additional information
-
high-throughput inhibitor screening method, counterscreen assay and ATP competition assay, overview
-
NIH-12848

-
-
NIH-12848
-
very specific inhibitor
NIH-12848
-
full designation NCGC00012848-02, specific inhibitor of isoform PI5P4Kgamma, does not inhibit the alpha and beta PI5P4K isoforms at concentrations up to 0.1 mM; inhibitor of isoform PI5P4Kgamma only
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.